Developer docs
API playgroundTry for free, no card

Search company profiles

Baccinex

Full company profile

uuid000k9zx

Namestring
Baccinex
Websiteurl
baccinex.com
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Baccinex is a full-service pharmaceutical contract manufacturing organization (CDMO) headquartered in Courroux, Switzerland. Founded in 1999, the company sits within a globally distributed CDMO platform that operates seven manufacturing sites across Switzerland (Courroux/Jura — heritage facility), France (Livron-sur-Drôme, Maisons-Alfort), Germany (Leipzig — corporate headquarters), Norway (Halden), Greece (Athens), and Japan (Kawagoe). The firmographic employee range is 1,001-5,000, though the Courroux site alone is cited at 110+ professionals across more than 20 disciplines on a 6,200 m² industrial footprint.

The company's technical core is aseptic fill-finish manufacturing of sterile pharmaceutical products filled into vials, in both lyophilized (freeze-dried) and liquid formats. Capabilities include lyophilization cycle development supported by a 3.5 m² lyophilizer, aseptic process simulation (media fills), formulation of complex modalities (peptides, biologics, monoclonal antibodies, controlled substances, small molecules, sterile suspensions, ophthalmics), and a broad in-house analytical release toolkit (HPLC/UPLC, Karl Fischer, sub-visible particle counting, SDS-PAGE, endotoxin and bioburden testing, sterility under isolator). The Courroux facility is dual-certified by Swissmedic (EU-GMP) and US-FDA. A no-minimum-batch-size policy and bulk-volume capacity from 200-300 ml position the firm for early-stage clinical customers, while commercial offerings extend to prefilled syringes, ampoules, IV bags, oral liquids, semi-solids, oral solids, and suppositories across the broader site network.

Baccinex operates a project-based B2B services model, billing on clinical production (Phase I/II/III), commercial production, analytical services, regulatory support, and packaging, with multi-year contracts and transparent quote-based pricing. Go-to-market is direct enterprise engagement with (bio)pharmaceutical companies of all sizes, supplemented by content marketing (Adragos Hub blog), industry events, and LinkedIn/YouTube presence. Customer evidence indicates a biotech-to-commercial relationship pattern — for example, the partnership with Igyxos to manufacture the first clinical batch of a first-in-class infertility mAb, which advanced into clinical phases and led to repeat production engagements.

Short descriptiontext

Baccinex is a full-service pharmaceutical contract manufacturing organization (CDMO) headquartered in Courroux, Switzerland, specializing in aseptic fill-finish of sterile liquid and lyophilized products for biotech and pharmaceutical clients across clinical and commercial stages.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCourroux, Switzerland
HQ citystring
Courroux
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical contract manufacturing, aseptic fill-finish, lyophilization services, sterile injectables manufacturing, GMP manufacturing services
Industry4 codes
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Contract Manufacturing
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Manufacturing Services
TypeProfessional Services
Description

Revenue generated through contract manufacturing services as a CDMO (Contract Development and Manufacturing Organization). Services include clinical production (Phase I, II, III), commercial production, analytical services, regulatory support, and packaging services. Billed based on project scope, batch size, and service complexity.

adragos-pharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales
Pricing details1 tier
1Custom project-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

No minimum batch size required, providing flexibility for projects of any scale. Pricing based on detailed quotations with full cost transparency.

adragos-pharma.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Baccinex is a full-service pharmaceutical contract manufacturing organization (CDMO) founded in 1999 in Courroux, Switzerland, specializing in aseptic manufacturing of sterile liquid and lyophilized (freeze-dried) pharmaceutical products. The company provides clinical production (Phase I, II, III), commercial production, lyophilization cycle development, analytical services, regulatory support, visual inspection, pharmaceutical packaging, controlled substance handling, cold chain distribution, and stability studies for biotechnology and pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Aseptic Fill-Finish Manufacturing
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Igyxos, a biotech company developing first-in-class monoclonal antibodies for infertility treatment, engaged Adragos Pharma as CDMO to produce their first clinical batch. The collaboration successfully advanced the mAb project into clinical phases, leading to additional production engagements.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

German-headquartered specialist in aseptic fill-finish of syringes, vials, and lyophilized biologics for clinical and commercial supply — directly comparable in core sterile manufacturing capability and customer profile to Baccinex.

TypeBroad incumbent
Description

Global CDMO with significant sterile fill-finish and lyophilization capacity for biologics across clinical and commercial stages — broader portfolio but directly overlaps Baccinex's core service offering.

3Recipharm
TypeDirect peer
Description

European CDMO with sterile injectable and lyophilization capabilities serving pharma and biotech customers across clinical and commercial production — closely aligned in service mix and customer segment.

TypeDirect peer
Description

German-headquartered CDMO offering sterile liquid and lyophilized fill-finish, oral solids, and semi-solids — direct competitor in European contract sterile manufacturing for pharma/biotech.

5Fareva
TypeDirect peer
Description

French-headquartered CDMO with sterile injectable and lyophilization capabilities across multiple European sites — directly comparable in aseptic fill-finish services and biotech customer base.

TypeDirect peer
Description

European contract manufacturer of sterile and non-sterile pharmaceutical forms including injectables and lyophilized products — comparable in formulation and fill-finish offerings.

TypeDirect peer
Description

US-based CDMO focused on sterile injectable fill-finish and lyophilization for biopharma — directly comparable in sterile manufacturing core, with overlapping biotech customer profile.

TypeDirect peer
Description

Swiss CDMO with sterile injectable and aseptic manufacturing capabilities — directly comparable in geographic positioning, regulatory profile, and biotech customer focus.

TypeBroad incumbent
Description

European CDMO offering sterile injectables, peptides, and biologics manufacturing — broader portfolio but significant overlap with Baccinex's sterile and peptide capabilities.

TypeDirect peer
Description

UK/Northern Ireland-based CDMO with aseptic fill-finish, lyophilization, and clinical supply services for pharma and biotech — directly comparable in clinical-stage sterile manufacturing services.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Baccinex

Pharmaceutical Contract Manufacturingbaccinex.com

Baccinex is a full-service pharmaceutical contract manufacturing organization (CDMO) headquartered in Courroux, Switzerland, specializing in aseptic fill-finish of sterile liquid and lyophilized products for biotech and pharmaceutical clients across clinical and commercial stages.

What Baccinex does

Baccinex is a full-service pharmaceutical contract manufacturing organization (CDMO) headquartered in Courroux, Switzerland. Founded in 1999, the company sits within a globally distributed CDMO platform that operates seven manufacturing sites across Switzerland (Courroux/Jura — heritage facility), France (Livron-sur-Drôme, Maisons-Alfort), Germany (Leipzig — corporate headquarters), Norway (Halden), Greece (Athens), and Japan (Kawagoe). The firmographic employee range is 1,001-5,000, though the Courroux site alone is cited at 110+ professionals across more than 20 disciplines on a 6,200 m² industrial footprint.

The company's technical core is aseptic fill-finish manufacturing of sterile pharmaceutical products filled into vials, in both lyophilized (freeze-dried) and liquid formats. Capabilities include lyophilization cycle development supported by a 3.5 m² lyophilizer, aseptic process simulation (media fills), formulation of complex modalities (peptides, biologics, monoclonal antibodies, controlled substances, small molecules, sterile suspensions, ophthalmics), and a broad in-house analytical release toolkit (HPLC/UPLC, Karl Fischer, sub-visible particle counting, SDS-PAGE, endotoxin and bioburden testing, sterility under isolator). The Courroux facility is dual-certified by Swissmedic (EU-GMP) and US-FDA. A no-minimum-batch-size policy and bulk-volume capacity from 200-300 ml position the firm for early-stage clinical customers, while commercial offerings extend to prefilled syringes, ampoules, IV bags, oral liquids, semi-solids, oral solids, and suppositories across the broader site network.

Baccinex operates a project-based B2B services model, billing on clinical production (Phase I/II/III), commercial production, analytical services, regulatory support, and packaging, with multi-year contracts and transparent quote-based pricing. Go-to-market is direct enterprise engagement with (bio)pharmaceutical companies of all sizes, supplemented by content marketing (Adragos Hub blog), industry events, and LinkedIn/YouTube presence. Customer evidence indicates a biotech-to-commercial relationship pattern — for example, the partnership with Igyxos to manufacture the first clinical batch of a first-in-class infertility mAb, which advanced into clinical phases and led to repeat production engagements.

Baccinex firmographics

Firmographics
Name
Baccinex
Website
https://baccinex.com
Company type
Private
Founded year
1999
Headcount range
11–50 employees
Short description
Baccinex is a full-service pharmaceutical contract manufacturing organization (CDMO) headquartered in Courroux, Switzerland, specializing in aseptic fill-finish of sterile liquid and lyophilized products for biotech and pharmaceutical clients across clinical and commercial stages.
Ownership category
akta.pro rank

Baccinex industry classification

Industry
Product category
Pharmaceutical Contract Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Pharmaceutical contract manufacturing
  • Aseptic fill-finish
  • Lyophilization services
  • Sterile injectables manufacturing
  • GMP manufacturing services

Where Baccinex is headquartered

Location

Headquarters

HQ city
Courroux
HQ country
Switzerland
HQ region
Europe

Offices7 records

Markets served

Baccinex business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

  1. Contract Manufacturing Services: Revenue generated through contract manufacturing services as a CDMO (Contract Development and Manufacturing Organization). Services include clinical production (Phase I, II, III), commercial production, analytical services, regulatory support, and packaging services. Billed based on project scope, batch size, and service complexity.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Baccinex product offering

Product offering

Core offering

Baccinex is a full-service pharmaceutical contract manufacturing organization (CDMO) founded in 1999 in Courroux, Switzerland, specializing in aseptic manufacturing of sterile liquid and lyophilized (freeze-dried) pharmaceutical products. The company provides clinical production (Phase I, II, III), commercial production, lyophilization cycle development, analytical services, regulatory support, visual inspection, pharmaceutical packaging, controlled substance handling, cold chain distribution, and stability studies for biotechnology and pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Aseptic Fill-Finish Manufacturing

Companies that use Baccinex

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Baccinex technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Baccinex partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • IgyxosminorStrategic or Co-development PartnerIgyxos, a biotech company developing first-in-class monoclonal antibodies for infertility treatment, engaged Adragos Pharma as CDMO to produce their first clinical batch. The collaboration successfully advanced the mAb project into clinical phases, leading to additional production engagements.

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Baccinex competitors and assessment

Company assessment

Direct peers

  • Vetter Pharma: German-headquartered specialist in aseptic fill-finish of syringes, vials, and lyophilized biologics for clinical and commercial supply — directly comparable in core sterile manufacturing capability and customer profile to Baccinex.
  • Recipharm: European CDMO with sterile injectable and lyophilization capabilities serving pharma and biotech customers across clinical and commercial production — closely aligned in service mix and customer segment.
  • Aenova: German-headquartered CDMO offering sterile liquid and lyophilized fill-finish, oral solids, and semi-solids — direct competitor in European contract sterile manufacturing for pharma/biotech.
  • Fareva: French-headquartered CDMO with sterile injectable and lyophilization capabilities across multiple European sites — directly comparable in aseptic fill-finish services and biotech customer base.
  • Delpharm: European contract manufacturer of sterile and non-sterile pharmaceutical forms including injectables and lyophilized products — comparable in formulation and fill-finish offerings.
  • Simtra BioPharma Solutions: US-based CDMO focused on sterile injectable fill-finish and lyophilization for biopharma — directly comparable in sterile manufacturing core, with overlapping biotech customer profile.
  • Carbogen Amcis: Swiss CDMO with sterile injectable and aseptic manufacturing capabilities — directly comparable in geographic positioning, regulatory profile, and biotech customer focus.
  • Almac Group: UK/Northern Ireland-based CDMO with aseptic fill-finish, lyophilization, and clinical supply services for pharma and biotech — directly comparable in clinical-stage sterile manufacturing services.

Broad incumbents

  • Catalent: Global CDMO with significant sterile fill-finish and lyophilization capacity for biologics across clinical and commercial stages — broader portfolio but directly overlaps Baccinex's core service offering.
  • CordenPharma: European CDMO offering sterile injectables, peptides, and biologics manufacturing — broader portfolio but significant overlap with Baccinex's sterile and peptide capabilities.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Baccinex social profiles

Digital presence

Baccinex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Baccinex leadership team

Management profile

Number of profiles

Baccinex funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Baccinex M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Baccinex

What does Baccinex do?

Baccinex is a full-service pharmaceutical contract manufacturing organization (CDMO) founded in 1999 in Courroux, Switzerland, specializing in aseptic manufacturing of sterile liquid and lyophilized (freeze-dried) pharmaceutical products. The company provides clinical production (Phase I, II, III), commercial production, lyophilization cycle development, analytical services, regulatory support, visual inspection, pharmaceutical packaging, controlled substance handling, cold chain distribution, and stability studies for biotechnology and pharmaceutical companies.

When was Baccinex founded?

Baccinex was founded in 1999. It employs 11 to 50 people.

Where is Baccinex based?

Baccinex is headquartered in Courroux, Switzerland, in the Europe region.

How does Baccinex make money?

One revenue line is on record: contract Manufacturing Services.

Who are Baccinex's main competitors?

Direct peers on record are Vetter Pharma, Recipharm, Aenova, Fareva, Delpharm, Simtra BioPharma Solutions, Carbogen Amcis and Almac Group. Broad incumbents are Catalent and CordenPharma.

Does Baccinex have an API?

No public API is recorded for Baccinex.

What industry is Baccinex in?

Baccinex's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals